Ann: Acrux Submits First-To-File Generic of Jublia, page-3

Given the current lack of generics for Jublia and Acrux's likely access to the 180 days of generic market exclusivity, I believe attributing a 10% market share would be extremely conservative.

With US revenues for Jublia around US$280 million and accounting for 25% royalties, this would equate to AUD$9.5 million pa. in revenue for ACR, beginning in 12 months.

Keeping in mind, this is just 1 out of 13 upcoming submissions, with the latter number likely to further increase. Even with today's 16% rise, a market cap of $26 million still makes this company the most undervalued I can currently find on the ASX.